Articles

The expansion will be designed to meet the growing demand for small molecule drug substance development and manufacturing.

Cambrex to Invest More than $50 Million into Iowa Site Expansion

The event will be rescheduled for Oct. 19–21, 2021 at the Javits Center in New York City. 

INTERPHEX 2021 Rescheduled Due to COVID-19

Moderna’s COVID-19 vaccine candidate can be distributed using widely available vaccine delivery and storage infrastructure.

Moderna Announces Extended Stability Conditions for COVID-19 Vaccine Candidate

The new facility, which is expected to be operational by mid-2026, will utilize cell-based technology to produce influenza vaccines for influenza pandemics and seasonal vaccination programs, both in Australia and globally. 

Seqirus to Invest $584 Million in Australian Biotech Manufacturing Facility

The companies will work together on research activities through to the selection of a preclinical candidate, after which Roche will handle further development and global commercialization.

Roche and Lead Pharma to Collaborate on Oral Small Molecule Development

The 110,000 ft2 site, which is set to be operational by the second half of 2021, will feature new technology including 2000-L scale bioreactors and additional fill-finish capabilities.

Vibalogics Establishes US Presence with Boston Virotherapy Manufacturing Facility

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

The first public announcement from the Biden-Harris transition team was to name members of a COVID-19 advisory board charged with initiating policies and actions to combat the fast-rising infection rate in the United States 

Tackling COVID Top Priority for New Administration 

Apeiron Biologics has selected Domainex to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b.

Apeiron Biologics Selects Domainex to Provide Integrated Lead Optimization Services

AstraZeneca has received approval for Calquence (acalabrutinib) to be used as a treatment of chronic lymphocytic leukemia (CLL) in adults within the European Union (EU).

Calquence Gains EU Approval for Treatment of Chronic Lymphocytic Leukemia

PhoreMost and Oxford Biomedica have entered into a discovery collaboration for the development of next-generation chimeric antigen receptor T-cell therapies.

News